KRT7 and bronchogenic carcinoma: The current study aimed at evaluating the utility of a panel of antibodies including TTF-1, P63, HMWK (34βE12), CK7, and cluster of differentiation (CD56) for accurate distinction of bronchogenic carcinomas.